1
|
Onaolapo AY, Ojo FO, Adeleye OO, Falade J, Onaolapo OJ. Diabetes Mellitus and Energy Dysmetabolism in Alzheimer's Disease: Understanding the Relationships and Potential Therapeutic Targets. Curr Diabetes Rev 2023; 19:e020123212333. [PMID: 36593701 DOI: 10.2174/1573399819666230102141154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 09/20/2022] [Accepted: 10/31/2022] [Indexed: 01/04/2023]
Abstract
Over the last century, there has been a gradual but sustained increase in life expectancy globally. A consequence of increased life expectancy is an associated rise in the prevalence of agerelated chronic debilitating neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease, Huntington's disease, and multiple sclerosis. These disorders, which are generally characterised by the loss of motor/sensory neurons and cognitive decline, have continued to confound researchers who are working tirelessly to define their pathogenetic mechanisms and develop effective therapies. In the last few years, there has been increasing evidence of the existence of a relationship between energy metabolism and neurodegeneration, with reports that type 2 diabetes mellitus increases the risk of AD. Evidence from preclinical and epidemiologic studies has associated dysmetabolism and dysmetabolic syndromes with the development of neurodegenerative changes. More recently, diabetes mellitus and energy dysmetabolism have been linked to the aetiopathogenesis of AD. Moreover, metabolic hormones, including ghrelin, leptin, insulin, and insulin-like growth factor (IGF)-1, have been reported to play key roles in the regulation of neuronal injury and loss in neurodegenerative diseases like AD. In this narrative review, we examine the current scientific evidence regarding the role of dysmetabolism (including diabetes mellitus and metabolic syndrome) in AD and how it impacts disease progression and the development of novel therapies in AD.
Collapse
Affiliation(s)
- Adejoke Y Onaolapo
- Department of Anatomy, Behavioural Neuroscience Unit, Neurobiology Subdivision, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria
| | - Folusho O Ojo
- Department of Anatomy, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria
| | - Olufunto O Adeleye
- Department of Mental Health, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria
| | - Joshua Falade
- Department of Mental Health, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria
| | - Olakunle J Onaolapo
- Department of Anatomy, Behavioural Neuroscience Unit, Neurobiology Subdivision, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria
| |
Collapse
|
2
|
Bian Y, Chen Y, Wang X, Cui G, Ung COL, Lu JH, Cong W, Tang B, Lee SMY. Oxyphylla A ameliorates cognitive deficits and alleviates neuropathology via the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways in vitro and in vivo murine models of Alzheimer's disease. J Adv Res 2022; 34:1-12. [PMID: 35024177 PMCID: PMC8655137 DOI: 10.1016/j.jare.2021.09.002] [Citation(s) in RCA: 29] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 08/09/2021] [Accepted: 09/05/2021] [Indexed: 12/16/2022] Open
Abstract
Introduction Alzheimer’s disease (AD) is a progressive brain disorder, and one of the most common causes of dementia and amnesia. Due to the complex pathogenesis of AD, the underlying mechanisms remain unclear. Although scientists have made increasing efforts to develop drugs for AD, no effective therapeutic agents have been found. Objectives Natural products and their constituents have shown promise for treating neurodegenerative diseases, including AD. Thus, in-depth study of medical plants, and the main active ingredients thereof against AD, is necessary to devise therapeutic agents. Methods In this study, N2a/APP cells and SAMP8 mice were employed as in vitro and in vivo models of AD. Multiple molecular biological methods were used to investigate the potential therapeutic actions of oxyphylla A, and the underlying mechanisms. Results Results showed that oxyphylla A, a novel compound extracted from Alpinia oxyphylla, could reduce the expression levels of amyloid precursor protein (APP) and amyloid beta (Aβ) proteins, and attenuate cognitive decline in SAMP8 mice. Further investigation of the underlying mechanisms showed that oxyphylla A exerted an antioxidative effect through the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways. Conclusions. Taken together, our results suggest a new horizon for the discovery of therapeutic agents for AD.
Collapse
Key Words
- AD, Alzheimer’s disease
- AOE, ethanolic extract of Alpinia oxyphylla
- APP, amyloid precursor protein
- ARE, antioxidant response element
- ARE, antioxidant responsive element
- Alzheimer’s disease
- Amyloid beta proteins
- Aβ, amyloid beta
- GSK3, glycogen synthase kinase 3
- HO-1, heme oxygenase-1
- Keap1, Keleh-like ECH-associated protein
- MWM, Morris Water Maze
- NFTs, neurofibrillary tangles
- NQO1, NAD(P)H:quinone oxidoreductase1
- Nrf2, erythroid-derived 2-related factor 2
- Oxidative stress
- PD, Parkinson’s disease
- PHF, paired helical filaments
- RLU, relative luciferase units
- ROS, reactive oxygen species
- SAMP8
- SAMP8 mice, senescence-accelerated mouse prone 8
- oxyphylla A
- pRL-TK, Renilla luciferase reporter plasmid
Collapse
Affiliation(s)
- Yaqi Bian
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.,Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao, China
| | - Yan Chen
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.,Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao, China
| | - Xiufen Wang
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.,Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao, China
| | - Guozhen Cui
- Department of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, China
| | - Carolina Oi Lam Ung
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.,Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao, China
| | - Jia-Hong Lu
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.,Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao, China
| | - Weihong Cong
- Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China
| | - Benqin Tang
- Department of Medical Science, Shunde Polytechnic, Foshan, China
| | - Simon Ming-Yuen Lee
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.,Department of Pharmaceutical Sciences, Faculty of Health Sciences, University of Macau, Macao, China
| |
Collapse
|